Markhot Ferenc Oktatokorhaz Es Rendelointezet
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Markhot Ferenc Oktatokorhaz Es Rendelointezet, researchers are exploring new strategies to lower the risk of stroke in patients who have experienced an acute ischemic event or a high‑risk transient ischemic attack. The study evaluates whether the oral agent milvexian can safely reduce recurrent ischemic episodes compared with standard care.
- Stroke recurrence prevention
- Antithrombotic efficacy assessment
- Safety profiling in acute stroke patients
The site’s multidisciplinary team of 24 investigators contributes to eight ongoing trials, with cardiovascular research representing a key focus of its clinical portfolio.
Eye Diseases
The ophthalmology department is conducting a trial to determine if citicoline eye drops can preserve visual fields in individuals with progressing open‑angle glaucoma, alongside routine clinical management. The goal is to improve visual outcomes and reduce disease progression.
- Visual field preservation
- Topical neuroprotection
- Glaucoma progression monitoring
With a dedicated group of ophthalmologists, the hospital leverages its expertise to address common eye conditions while participating in the broader network of eight clinical studies.
Hemic and Lymphatic Diseases
Investigators are testing whether adding XEMBIFY to standard therapy can lower the frequency of serious bacterial infections in patients with B‑cell chronic lymphocytic leukemia, multiple myeloma, or non‑Hodgkin lymphoma who have hypogammaglobulinemia. The trial aims to enhance infection control in these vulnerable populations.
- Infection reduction in hematologic malignancies
- Immunoglobulin deficiency management
- Combination therapy safety evaluation
The hospital’s hematology unit collaborates closely with oncology specialists to bring innovative treatments to patients with blood‑related cancers.
Neoplasms
A separate study compares luspatercept with epoetin alfa in low‑risk myelodysplastic syndrome patients to see which agent better promotes red blood cell production and reduces transfusion dependence. This research seeks to improve quality of life for individuals with this bone‑marrow disorder.
- Anemia management in MDS
- Erythropoiesis‑stimulating agents comparison
- Transfusion reduction strategies
Through its eight active trials, the center integrates cancer research across hematologic and solid‑tumor domains, supported by a robust team of 24 investigators.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Markhot Ferenc Oktatokorhaz Es Rendelointezet
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.